

12

Name of Journal: *World Journal of Clinical Cases*

Manuscript NO: 61573

Manuscript Type: CASE REPORT

Roxadustat as treatment for a blood transfusion-dependent maintenance hemodialysis patient: A case report and review of literature

Renal anemia

Abstract

BACKGROUND

Erythropoiesis-stimulating agents (ESAs) have revolutionized the therapeutic strategy for anemia in chronic kidney disease (CKD). However, some cases are resistant or hyporesponsive to ESAs. Roxadustat is an oral hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor that stimulates erythropoiesis and regulates iron metabolism. Here, we describe a hemodialysis patient with refractory anemia who did not respond to traditional treatments and depended on blood transfusion for more than one year.

Match Overview

1	Crossref 48 words Neil S. Sanghani, Volker H. Haase. "Hypoxia-Inducible Factor Activators in Renal Anemia: Current Clinical Experience"	2%
2	Internet 38 words crawled on 17-Mar-2020 www.nejm.org	2%
3	Internet 31 words crawled on 05-May-2020 www.wjgnet.com	1%
4	Internet 18 words crawled on 26-Jul-2019 tessera.spandidos-publications.com	1%
5	Internet 15 words crawled on 10-Mar-2020 worldwidescience.org	1%
6	Crossref 15 words Zuo-Lin Li, Yan Tu, Bi-Cheng Liu. "Treatment of Renal Anemia with Roxadustat: Advantages and Achievement", <i>Kidney International</i>	1%
7	Crossref 15 words Qin Yang, Xin Wang. "A case report of rhabdomyolysis caused by the use of roxadustat in the treatment of caused by..."	1%
8	Internet 14 words crawled on 21-Sep-2020 journals.lww.com	1%



ALL

IMAGES

VIDEOS

38,600 Results

Any time ▾

Roxadustat Treatment for Anemia in Patients Undergoing ...

<https://www.nejm.org/doi/full/10.1056/NEJMoa1901713>

Jul 24, 2019 · The intermittent dosing strategy with **roxadustat** for the **treatment** of anemia 17 in **patients** with chronic kidney disease was developed to permit durable **maintenance** of effect. 18-20 With a half ...

Cited by: 142

Author: Nan Chen, Chuanming Hao, Bi-Cheng Liu, H...

Publish Year: 2019

EXPLORE FURTHER

[Roxadustat | FibroGen | HIF-PHI for Anemia in CKD, MDS](#)

www.fibrogen.com

[Roxadustat FDA Approval Status - Drugs.com](#)

www.drugs.com

Recommended to you based on what's popular • Feedback

Roxadustat for Anemia in Patients with Kidney Disease Not ...

<https://www.nejm.org/doi/full/10.1056/NEJMoa1813599>

Jul 24, 2019 · **Roxadustat** in **Patients** Not Receiving **Dialysis** This phase 3, randomized trial in China compared the efficacy and safety of **roxadustat**, an oral hypoxia-inducible factor ...

Cited by: 178

Author: Nan Chen, Chuanming Hao, Xiaomei Peng, ...

Publish Year: 2019

PEOPLE ALSO ASK

How effective is Roxadustat for chronic kidney disease? ▾

Can hemodialysis cause adverse outcomes? ▾

ALL

IMAGES

VIDEOS

MAPS

NEWS

SHOPPING

39,200 Results

Any time ▾

Open links in new tab



Roxadustat Treatment for Anemia in Patients Undergoing ...

<https://www.nejm.org/doi/full/10.1056/NEJMoa1901713>

Jul 24, 2019 · The intermittent dosing strategy with **roxadustat** for the **treatment** of anemia 17 in **patients** with chronic kidney disease was developed to permit durable **maintenance** of effect. 18-20 With a half ...

Cited by: 152

Author: Nan Chen, Chuanming Hao, Bi-Cheng Liu, H...

Publish Year: 2019

EXPLORE FURTHER

Roxadustat | FibroGen | HIF-PHI for Anemia in CKD, MDS

www.fibrogen.com

Roxadustat FDA Approval Status - Drugs.com

www.drugs.com

Recommended to you based on what's popular • Feedback

(PDF) Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia ...

<https://www.researchgate.net/publication/292677208...>

Background: **Roxadustat** is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor approved in China for **dialysis-dependent CKD anemia**. Methods: This phase 3, 24-week, double-blind, double ...

Roxadustat for Anemia in Patients with Kidney Disease Not ...

<https://www.nejm.org/doi/full/10.1056/NEJMoa1813599>

Jul 24, 2019 · **Roxadustat** in **Patients** Not Receiving **Dialysis** This phase 3, randomized trial in China compared the efficacy and safety of **roxadustat**, an oral hypoxia-inducible factor ...

Cited by: 185

Author: Nan Chen, Chuanming Hao, Xiaomei Peng, ...

Publish Year: 2019

Whether Prolyl Hydroxylase Blocker-Roxadustat-In the ...

<https://europepmc.org/article/MED/33567688> ▾

There are currently more than 15 phase 3 clinical trials underway with a target enrollment of about 10,000 **patients** worldwide, studying the safety, efficacy, and long-term effects of **roxadustat** in CKD **patients**, including non-**dialysis**-dependent [23,24,25,26], **hemodialysis**-dependent [22,25,27,28,29] and peritoneal **dialysis**-dependent subjects [25 ...

Roxadustat Treatment of Chronic Kidney Disease-Associated ...